The Indian Competition Authority fines merging parties for failure to disclose the global acquisition of a healthcare antisepsis business (Schulke / ASP Division of Ethicon)

Sharma, Man Mohan

Previous article The US FTC challenges a merger using a monopolization theory to allege that the merger would eliminate nascent competition in the therapeutic adrenocorticotropic hormones (Questcor Pharmaceuticals / Mallinckrodt) Next article The EU Commission clears a merger subject to remedies in the pharmaceutical sector (Abbott Laboratories / St Jude Medical)

13 Jan 2017

The Indian Competition Authority fines merging parties for failure to disclose the global acquisition of a healthcare antisepsis business (Schulke / ASP Division of Ethicon)

KEYWORDS

Reference

Indian Competition Authority, Schulke / ASP Division of Ethicon, Combination Registration No.C-2015/12/349, 13 January 2017

CCI penalizes Schulke and Mayr GmBH (Schulke) for delayed filing in relation to the acquisition of Healthcare Antisepsis Solutions (HAS) business of Johnson & Johnson Private Limited (JJPL)* CCI, by its order dated January 13, 2017 has imposed a penalty of INR 25,00,000 on Schulke on account of their failure to notify the commission about its global acquisition of Ethicon Inc.’s Healthcare antisepsis (HAS) business. On April 23, 2015, Schulke has entered into a Global Asset Purchase Agreement (GAPA) for

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Man Mohan Sharma
Vaish Associates Advocates (New Delhi)

India 263 contributions 41154 visits

Quotation

Man Mohan Sharma, The Indian Competition Authority fines merging parties for failure to disclose the global acquisition of a healthcare antisepsis business (Schulke / ASP Division of Ethicon), 13 January 2017, e-Competitions Pharma & Mergers, Art. N° 87604

Visites 214